本帖最后由 老马 于 2012-1-13 21:20 编辑
* V- `) n* X5 F4 O' K: P/ B+ Y/ u0 |& M4 Q
爱必妥和阿瓦斯丁的比较
: {( k5 U$ Q9 @& a; z0 f: E
% A# M9 V6 `6 p" C5 x2 g' Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ k! s# N) i7 U T6 g, M
% H P0 |; t! q* R0 f! b) N7 |
, G* W8 P# K A. r0 }http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 G. b+ O2 _: x2 N/ T2 W |==================================================
- N+ c$ v- k5 ]2 }4 LOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ i5 z$ l1 }7 a4 Q" s, R8 J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
2 ?: i3 p7 G+ A8 F! h* MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' v! Y% [" w% o/ }2 p
|